SCNI 424B3: Secondary offering

Scinai Immunotherapeutics

Filed with the SEC on · accession 0001213900-26-117817

SCNI filed a 424B3 (prospectus (offering)) with the SEC on Nov 10, 2026. Scinai Immunotherapeutics filed a 424B3 prospectus covering the resale of up to 7,587,543 American Depositary Shares by selling shareholders, consisting of shares issuable upon exercise of pre-funded warrants, Series A-1 warrants, and placement agent warrants issued in an October 2026 private… The stock moved +7.0% by the first close after the filing.

Summary of the filing

Scinai Immunotherapeutics filed a 424B3 prospectus covering the resale of up to 7,587,543 American Depositary Shares by selling shareholders, consisting of shares issuable upon exercise of pre-funded warrants, Series A-1 warrants, and placement agent warrants issued in an October 2026 private placement. The company will not receive proceeds from resales, though it may receive warrant exercise prices if exercised for cash.

Key details

Aggregate ADSs registered for resale$7.6M
Last reported sale price per ADS on Nasdaq$0
ADSs issuable upon exercise of pre-funded warrants$2.5M
ADSs issuable upon exercise of Series A-1 warrants$3.7M
ADSs issuable upon exercise of additional Series A-1 warrants$1.3M
ADSs issuable upon exercise of placement agent warrants$123K
IssuerScinai Immunotherapeutics Ltd.
Placement agentA.G.P./Alliance Global Partners

How SCNI stock reacted

Close before

$0.46

Nov 9, 2026

First close after

+7.03%

$0.49

5 trading days

-15.33%

$0.39

Since filing

-15.33%

$0.39

✦ Ask GOAX AI about this filing — what it means for SCNI, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for SCNI?

Click here

Frequently asked questions

What did SCNI file with the SEC on Nov 10, 2026?

SCNI filed a 424B3 (Secondary offering). Scinai Immunotherapeutics filed a 424B3 prospectus covering the resale of up to 7,587,543 American Depositary Shares by selling shareholders, consisting of shares issuable upon exercise of pre-funded warrants, Series A-1 warrants, and placement agent warrants issued in an October 2026 private placement. The company will not receive proceeds from resales, though it may receive warrant exercise prices if exercised for cash.

What does a secondary offering mean for SCNI stock?

New shares dilute existing holders and are often sold at a discount to the market price.

How do I read a 424B3?

The final terms of an offering of shares or bonds. Look at price, number of shares and the discount to the market price. Large offerings dilute existing shareholders.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 424B3 (prospectus (offering)): The final terms of an offering of shares or bonds.

How did SCNI stock react to this filing?

SCNI closed at $0.46 before the filing and $0.49 on Nov 10, 2026 (+7.03%). Five trading days later: $0.39 (-15.33%).

Other SCNI SEC filings

Get alerts when SCNI files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days